Vyant Bio, Inc.·4/A

Dec 29, 4:30 PM ET

LaFrence Andrew D.C. 4/A

4/A · Vyant Bio, Inc. · Filed Dec 29, 2021

Insider Transaction Report

Form 4/AAmended
Period: 2021-11-23
LaFrence Andrew D.C.
Chief Financial Officer
Transactions
  • Purchase

    Common Stock, $0.0001 par value

    2021-11-23$2.00/sh+5,000$9,99834,292 total
Holdings
  • Common Stock, $0.0001 par value

    (indirect: By Trust)
    29,825
Footnotes (2)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.9995 to $2.00 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
  • [F2]Includes 3,000 shares previously held directly by the Reporting Person which were transferred to this joint trust account.

Documents

1 file
  • 4
    ownership.xml